Crizotinib - a novel multikinase inhibitor of signalling pathways for treatment in selected patients with non-small cell lung cancwer
2013
Abstract
Crizotinib (PF O2341066) is a new drug approved in the European Union for the second and further lines of treatment in patients with non-small cell lung cancer (NSCLC), where the translocation of a gene for anaplastic lymphoma kinase(ALK) in the tissues was proven. Recently, its effectiveness was demonstrated among patients with NSCLC carrying the ROS1 gene conversion.
Crizotinib is an effective and safe drug for selected patients; targeted studies show its benefits in evaluating the frequency in response, reducing the symptoms of tumour disease, prolonging the time to progression as well as prolonging the life of patients. This drug has a good safety profile and good tolerability.